Number |
37 |
16 |
53 |
42,365 |
Angioedema cohort, % |
69.81 |
30.19 |
100.00 |
— |
ALLHAT cohort, % |
0.087 |
0.038 |
0.12 |
99.88 |
Age, mean (SD), y |
66.6 (8.35) |
65.1 (6.81) |
66.2 (7.88) |
66.9 (7.72) |
Age group, n (%), y |
55–65 |
19 (51.35) |
9 (56.25) |
28 (52.83) |
20,099 (47.44) |
66–75 |
11 (29.73) |
7 (43.75) |
18 (33.96) |
16,182 (38.20) |
Women, n (%) |
13 (35.14) |
8 (50.00) |
21 (39.62) |
19,820 (46.78) |
Race, n (%) |
Black |
23 (62.16) |
6 (37.50) |
29 (54.72) |
15,055 (35.54) |
Nonblack |
14 (37.84) |
10 (62.50) |
24 (45.28) |
27,309 (64.46) |
On blood pressure treatment ≥2 mo |
31 (83.78) |
14 (87.50) |
45 (84.91) |
36,791 (86.84) |
On blood pressure treatment <2 mo |
3 (8.11) |
0 (0.00) |
3 (5.66) |
1425 (3.36) |
Untreated at baseline |
3 (8.11) |
2 (12.50) |
5 (9.43) |
4148 (9.79) |
Current smoker |
14 (37.84) |
5 (31.25) |
19 (35.85) |
9250 (21.84) |
History of diabetes |
4 (10.81) |
2 (12.50) |
6 (11.32) |
15,277 (36.06) |
History of CHD |
10 (27.03) |
6 (37.50) |
16 (30.19) |
10,750 (25.37) |
Aspirin use§ |
14 (37.84) |
5 (31.25) |
19 (35.85) |
15,204 (35.89) |
Estrogen use (women) |
9 (69.23) |
1 (12.5) |
10 (47.62) |
3491 (17.59) |
Visit 1 blood pressure, mean (SD)
Treated ≥2 mo |
SBP, mm Hg |
139.3 (15.71) |
142.0 (10.65) |
140.2 (14.26) |
142.7 (12.96) |
DBP, mm Hg |
82.1 (8.10) |
84.9 (5.32) |
82.9 (7.41) |
82.3 (9.52) |
Treated <2 mo |
SBP, mm Hg |
167.3 (7.09) |
— |
167.3 (7.09) |
158.1 (13.32) |
DBP, mm Hg |
92.7 (11.24) |
— |
92.7 (11.24) |
89.4 (9.76) |
BMI, mean (SD) (kg/m2) |
29.4 (7.61) |
29.5 (6.66) |
29.4 (7.27) |
29.7 (6.15) |
Serum potassium, mean (SD) (mEq/dL)§ |
4.1 (0.50) |
4.1 (0.44) |
4.1 (0.47) |
4.3 (0.51) |
Fasting glucose, mean (SD) (mg/dL) |
106.7 (28.72) |
121.0 (60.90) |
111.2 (41.41) |
123.0 (57.06) |
Creatinine, mean (SD) (mg/dL)§ |
1.08 (0.33) |
0.92 (0.13) |
1.03 (0.29) |
1.02 (0.30) |
Total cholesterol, mean (SD) (mg/dL)§ |
204.4 (33.27) |
220.7 (36.50) |
209.4 (34.74) |
215.9(43.2) |
For each characteristic, 2‐proportion or 2‐sample mean difference tests were performed comparing each of the 3 nondiuretic groups with chlorthalidone, respectively. ALLHAT indicates Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial; CHD, coronary heart disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; and BMI, body mass index. *Two participants with angioedema reported open‐label (nonassigned study drug) angiotensin‐converting enzyme inhibitor use: one was assigned to step 1 chlorthalidone and one to step 1 lisinopril. †Comparisons between treatment groups of baseline characteristics among those without angioedema showed no significant differences. ‡Non‐lisinopril treatment groups included chlorthalidone, amlodipine, and doxazosin. §Aspirin use was available for 52 participants; serum potassium, creatinine, and total cholesterol were available for 50 participants; and fasting glucose was available for 41 participants; there were no statistically significant differences (type 1 error probability of .05) between lisinopril and non‐lisinopril groups. |